课题基金 / 基金详情

NSF/FDA Scholar In Residence: 3D Printed Biomaterials for MSC Attachment and Targeted Differentiation

NSF/FDA Scholar In Residence: 3D Printed Biomaterials for MSC Attachment and Targeted Differentiation
NSF/FDA 常驻学者:用于 MSC 附着和靶向分化的 3D 打印生物材料
批准号:
1445700
负责人:
John Fisher
金额:
$12.67万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-01-01 至 2017-12-31

项目摘要

项目成果

John Fisher的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PI: Fisher, John P.Proposal: 1445700Title: NSF/FDA Scholar In Residence: 3D Printed Biomaterials for MSC Attachment and Targeted DifferentiationSignificanceThe clinical promise of tissue engineering and regenerative medicine will likely depend upon a viable strategy for the isolation, culture, and delivery of stem cells. Therefore, the U.S. Food and Drug Administration (FDA) must be on the forefront of stem cell biology. Although a variety of stem cell populations exist, autogenic and allogeneic mesenchymal stem cells are among the most widely investigated population owing to their ability to be readily differentiated into any of the mesodermal tissues, including bone, cartilage, fat, tendon, and ligament. Currently an enriched population of MSCs is obtained by differential centrifugation and/or plastic adherence. While both of these methods yield an enriched MSC population, neither offers a means to isolate and subsequently culture MSCs in one step. Most critically, these methods are only useful for in vitro culture of MSCs. The PI proposes the development of a modified biomaterial that can capture, culture, and differentiate an enriched MSC population, resulting in phenotypically stable chondrocytes. The proposed work will allow the FDA to remain on the forefront of stem cell technologies, both in the techniques utilized in the development of biomaterials for regenerative medicine and the interaction of stem cells with novel biomaterials. Finally, this work will promote FDA?s regulatory role by developing the in-house expertise to evaluate stem cell based technologies.Technical DescriptionMesenchymal stem cells (MSCs), a multipotent stem cell line, have tremendous therapeutic potential, as they are capable of differentiating into various lineages such as bone, adipose, and cartilage. However, MSCs represent only a fraction of the cells that are found in the bone marrow and adipose tissue and lack unique identifying markers, which increases the difficulty of isolation. The goal of this proposed work is to develop a tissue engineering strategy to characterize MSC isolation based on adhesion, and to mimic the specific adhesive interactions on the surface of a biodegradable biomaterial to capture, culture, and differentiate MSCs for engineered cartilage tissue applications. To this end, the PI proposes to develop a device that will allow for in vivo recruitment and enrichment of MSCs, as well as provide a simple method for in vitro capture of MSCs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NSF/FDA SIR: 3D Human Stem Cell Cardiac Model for Cardiac Electrophysiology Medical Device Safety Assessment
Collaborative Research: 4D Bioprinting of Near-infrared Light Responsive Smart Constructs for Pluripotent Stem Cell Derived Cardiomyocyte Engineering
NSF/FDA Scholar In Residence: 3D Cell Adhesion Assay for Cellularized Scaffold Characterization and Enhancement
Biohybrid Strategies for Decellularized Tissues
国内基金
海外基金
FDA上市药物库筛选鉴定靶向治疗ARID1A缺陷型结直肠癌的合成致死效应及分子机制研究
  • 批准号:
    82373165
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李爱民
  • 依托单位:
多维互质结构FDA雷达稀疏空时距自适应处理研究
  • 批准号:
    61771317
  • 项目类别:
    面上项目
  • 资助金额:
    62.0万元
  • 批准年份:
    2017
  • 负责人:
    阳召成
  • 依托单位:
基于FDA标记畸胎瘤细胞联合人胎盘屏障体外模型建立中药胚胎毒性评价体系的研究
  • 批准号:
    81573740
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2015
  • 负责人:
    宋殿荣
  • 依托单位: